KPMGMountain View, CA
Stephen B. Thau
Pain treatment is big business, with several multi-billion dollar per year pain therapeutics on the market, and several others with sales of more than $100 million per year. Misuse and abuse of pain drugs is also a big problem. According to the FDA, the misuse and abuse of pain therapies has increased significantly in the past five years. Looking to reverse this trend, the FDA is requiring manufacturers of opioid products to implement Risk Evaluation and Mitigation (REMS) strategies, which the agency is in the process of developing. On May 28, our panel of experts will discuss how the new REMS guidelines will change the landscape of pain therapies.
Moderator:Stephen ThauCo-chair, Life Sciences Practice, Morrison & Foerster LLP
Panelists:Michael Leong, MDPain Medicine Specialist, Adjunct Assistant Professor, Stanford University Pain Management Center
Gayle MillsExecutive Vice President, Business Operations, ROXRO Pharma, Inc.
Pamela PalmerChief Medical Officer, AcelRx Pharmaceuticals, Inc.
©1996-2018 Morrison & Foerster LLP. All rights reserved.